341 related articles for article (PubMed ID: 31786737)
1. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
Emond B; El Khoury AC; Patel C; Pilon D; Morrison L; Zhdanava M; Lefebvre P; Tandon N; Joshi K
Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
[TBL] [Abstract][Full Text] [Related]
3. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization.
El Khoury A; Patel C; Huang A; Wang L; Bashyal R
Curr Med Res Opin; 2019 Dec; 35(12):2159-2168. PubMed ID: 31366251
[No Abstract] [Full Text] [Related]
4. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis.
Patel C; Khoury AE; Huang A; Wang L; Bashyal R
Curr Ther Res Clin Exp; 2020; 92():100587. PubMed ID: 32714469
[TBL] [Abstract][Full Text] [Related]
6. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
7. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
8. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate.
Emond B; Joshi K; Khoury ACE; Lafeuille MH; Pilon D; Tandon N; Romdhani H; Lefebvre P
Pharmacoecon Open; 2019 Jun; 3(2):177-188. PubMed ID: 30088229
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
12. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
Joshi K; Lafeuille MH; Kamstra R; Tiggelaar S; Lefebvre P; Kim E; Yue Y; Tandon N
J Comp Eff Res; 2018 Feb; 7(2):121-133. PubMed ID: 28809128
[TBL] [Abstract][Full Text] [Related]
13. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
14. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
Kamstra R; Pilon D; Lefebvre P; Emond B; Joshi K
Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
[TBL] [Abstract][Full Text] [Related]
16. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
[TBL] [Abstract][Full Text] [Related]
18. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics.
Lafeuille MH; Tandon N; Tiggelaar S; Kamstra R; Lefebvre P; Kim E; Yue Y; Joshi K
Drugs Real World Outcomes; 2018 Mar; 5(1):81-90. PubMed ID: 29363022
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
[TBL] [Abstract][Full Text] [Related]
20. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
Patel C; Emond B; Morrison L; Lafeuille MH; Lefebvre P; Lin D; Kim E; Joshi K
Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]